Article

NSAID-Associated Risks for Patients with Heart Disease

Author(s):

Researchers warn that non-steroidal anti-inflammatory drugs (NSAIDs) are more dangerous than previously thought, and should be prescribed with great care among patients with heart disease.

Non-steroidal anti-inflammatory drugs (NSAIDs) are more dangerous than previously thought, and should be prescribed with great care among patients with heart disease, according to findings published in the European Heart Journal.

Researchers from Aarhus University in Denmark tested newer, selective COX-2 inhibitors (coxibs) in order to evaluate their gastrointestinal toxicity and anti-inflammatory properties. The researchers added that it has previously been understood that NSAIDs can cause fluid retention and elevate blood pressure in heart disease patients, which could increase the likelihood of a cardiovascular activity. But, they said, the main cause for concern when using these drugs is the risk for gastrointestinal bleeding.

“It’s been well known for a number of years that newer types of NSAIDs increase the risk of heart attacks,” said Morten Schmidt, MD, PhD, in a press release. “For this reason, a number of these newer types of NSAIDs have been taken off the market again. We can now see that some of the older NSAID types, particularly Diclofenac, are also associated with an increased risk of heart attack and apparently to the same extent as several of the types that were taken off the market. This is worrying, because these older types of medicine are frequently used throughout the western world and in many countries available without prescription.”

The study, which was conducted across 14 European universities and hospitals, concluded that NSAIDs should only be sold as over the counter drugs when it has an “adequate warning” about the links and risks to cardiovascular events. Additionally, the study authors added, NSAIDs should not be used in patients who have or at risk for cardiovascular disease.

“Many European countries consume more of these drugs than Denmark,” Schmidt added. Plus, the authors noted that in Denmark, NSAIDs are sold in low doses without a prescription (ibuprofen 200 mg/ tablet) or in higher doses and other types with prescriptions. “But we can still do better and it’s often the case that paracetamol, physiotherapy, mild opioids or other types of NSAIDs with less risk for the heart would be better for the patients. Of course, the recommendations that have been introduced following our study and its review of the heart related risks are a big step in the right direction in relation to patient safety.”

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.